{"id":"paricalcitol-zemplar","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypercalcemia"},{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Elevated calcium-phosphate product"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paricalcitol binds to and activates the vitamin D receptor (VDR), a nuclear receptor that regulates gene expression involved in calcium and phosphate metabolism. By activating VDR in the parathyroid glands, it suppresses parathyroid hormone (PTH) production, thereby reducing secondary hyperparathyroidism. Unlike calcitriol, paricalcitol has selective VDR activation with reduced effects on intestinal calcium absorption and bone resorption, resulting in a better therapeutic window.","oneSentence":"Paricalcitol is a selective vitamin D receptor agonist that activates the vitamin D receptor to regulate calcium and phosphate homeostasis and suppress parathyroid hormone secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:52.797Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis"},{"name":"Secondary hyperparathyroidism in patients with chronic kidney disease stages 3-4 (non-dialysis)"}]},"trialDetails":[{"nctId":"NCT04617067","phase":"PHASE2","title":"Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2020-10-16","conditions":"Advanced Pancreatic Cancer","enrollment":15},{"nctId":"NCT01725113","phase":"PHASE4","title":"Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol","status":"TERMINATED","sponsor":"Winthrop University Hospital","startDate":"2012-11","conditions":"Kidney Failure, Secondary Hyperparathyroidism, Hyperphosphatemia","enrollment":16},{"nctId":"NCT02930902","phase":"PHASE1","title":"Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-02-20","conditions":"Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7","enrollment":9},{"nctId":"NCT03331562","phase":"PHASE2","title":"A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer","status":"COMPLETED","sponsor":"Translational Genomics Research Institute","startDate":"2017-12-27","conditions":"Pancreatic Cancer, Pancreas Adenocarcinoma, Advanced Pancreatic Cancer","enrollment":24},{"nctId":"NCT02686827","phase":"PHASE2","title":"DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients.","status":"COMPLETED","sponsor":"Laurian Jongejan","startDate":"2015-10","conditions":"Hypersensitivity","enrollment":44},{"nctId":"NCT00752102","phase":"PHASE4","title":"Vitamin D and Coronary Calcification Study","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2008-09","conditions":"Chronic Kidney Disease, Vitamin D Deficiency, Coronary Calcification","enrollment":44},{"nctId":"NCT02273570","phase":"NA","title":"Optimal Anemia Treatment in End Stage Renal Disease (ERSD)","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Sant'Anna","startDate":"2015-03","conditions":"Hyperparathyroidism, Secondary","enrollment":50},{"nctId":"NCT00463021","phase":"PHASE4","title":"A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-04","conditions":"Secondary Hyperparathyroidism","enrollment":36},{"nctId":"NCT00135304","phase":"PHASE4","title":"ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-08","conditions":"Secondary Hyperparathyroidism","enrollment":170},{"nctId":"NCT01630408","phase":"NA","title":"The Effects of Active VItamin D on Left Atrial Volume Index","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-03","conditions":"Heart Failure","enrollment":""},{"nctId":"NCT00587158","phase":"NA","title":"Oral Paricalcitol in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-01","conditions":"Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary","enrollment":100},{"nctId":"NCT01273597","phase":"","title":"Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-01","conditions":"Kidney Failure, Chronic","enrollment":60},{"nctId":"NCT01442272","phase":"PHASE4","title":"Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D","status":"UNKNOWN","sponsor":"Hospital Universitario de Canarias","startDate":"2012-01","conditions":"Kidney Failure, Chronic, Disorder of Vitamin D","enrollment":174},{"nctId":"NCT00091975","phase":"PHASE3","title":"Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-08","conditions":"Kidney Disease","enrollment":78},{"nctId":"NCT00257920","phase":"PHASE4","title":"A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-06","conditions":"Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["C"],"phase":"marketed","status":"active","brandName":"Paricalcitol: Zemplar®","genericName":"Paricalcitol: Zemplar®","companyName":"Hospital Universitario de Canarias","companyId":"hospital-universitario-de-canarias","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paricalcitol is a selective vitamin D receptor agonist that activates the vitamin D receptor to regulate calcium and phosphate homeostasis and suppress parathyroid hormone secretion. Used for Secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis, Secondary hyperparathyroidism in patients with chronic kidney disease stages 3-4 (non-dialysis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}